Condition: Acute Myeloid Leukemia (AML) · Sponsor: iCell Gene Therapeutics
This single-arm, open-label phase I trial evaluates the safety and tolerability of ICG415, autologous CAR-T cells targeting CD33 and CLL1, in patients with relapsed or refractory acute myeloid leukemia (AML). Subjects receive lymphodepleting chemotherapy followed by autologous CAR-T infusion. The primary goal is to assess safety and preliminary anti-leukemic efficacy in patients failing standard AML therapies.
This description comes directly from the study's public registry record.
Yu Min · +86 150 7902 9006 · 625668742@qq.com
Li Fei · +86 139 7003 8386 · yx021021@sina.com
Always discuss trial participation with your own doctor first.
| Jiangxi Provincial People's Hospital (Participating Site) | Nanchang, Jiangxi, China | Recruiting |
| The First Affiliated Hospital of Nanchang University (Lead Site) | Nanchang, Jiangxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07668557